NFJ Investment Group LLC Has $2.82 Million Holdings in Omnicell, Inc. $OMCL

NFJ Investment Group LLC lessened its stake in Omnicell, Inc. (NASDAQ:OMCL) by 26.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 62,164 shares of the company’s stock after selling 22,193 shares during the quarter. NFJ Investment Group LLC’s holdings in Omnicell were worth $2,816,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Dana Investment Advisors Inc. acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $3,445,000. Assenagon Asset Management S.A. boosted its holdings in shares of Omnicell by 83.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock valued at $11,698,000 after buying an additional 117,556 shares during the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $4,804,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Omnicell by 345.9% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock valued at $971,000 after buying an additional 24,738 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Omnicell by 71.1% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock valued at $6,343,000 after buying an additional 58,193 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

OMCL opened at $37.83 on Monday. Omnicell, Inc. has a 1-year low of $26.84 and a 1-year high of $55.00. The stock’s fifty day simple moving average is $40.43 and its 200 day simple moving average is $41.52. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.72 billion, a PE ratio of 85.98, a price-to-earnings-growth ratio of 0.98 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the prior year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, research analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on OMCL. Wells Fargo & Company increased their price objective on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, April 23rd. Craig Hallum restated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Finally, Benchmark restated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $59.86.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president owned 112,783 shares in the company, valued at $4,874,481.26. This trade represents a 4.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. The trade was a 1.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.